Large meta-analysis of 124 randomized controlled studies covering 201 treatment strata found that plant sterol and stanol intakes of 0.6 to 3.3 g/day gradually reduce LDL-cholesterol concentrations by an average of 6 to 12%. The LDL-cholesterol-lowering effect continued to increase up to intakes of approximately 3 g/day, reaching an average effect of about 12%. When plant sterols and plant stanols were analyzed separately, clear and comparable dose-response relationships were observed for both, with no meaningful difference between them.

Meta-analysis of 84 trials with 141 treatment arms established a continuous dose-response relationship for the LDL-cholesterol-lowering effect of phytosterol intake. The analysis confirmed dose-dependent efficacy and generated predictive equations for estimating LDL-C reduction at any given phytosterol dose. Importantly, no significant differences were found between dose-response curves for plant sterols versus stanols, fat-based versus non-fat-based food formats, or dairy versus non-dairy delivery vehicles. This study was instrumental in establishing that the LDL-lowering effect is driven primarily by phytosterol dose rather than by the specific sterol type or food matrix.

European Atherosclerosis Society Consensus Panel position statement concluded that plant sterols and stanols at 2 g/day reduce LDL-cholesterol by 8 to 10% through inhibition of intestinal cholesterol absorption. The panel endorsed their use as an adjunct to lifestyle changes in individuals with elevated LDL-cholesterol who do not yet qualify for pharmacotherapy, as an addition to statin therapy for patients who fail to reach LDL-cholesterol targets on statins alone, and for adults and children with familial hypercholesterolaemia. The panel noted that adding plant sterols or stanols to statin therapy provides additional LDL lowering equivalent to doubling the statin dose. Safety in the general population was affirmed, with the exception of individuals with sitosterolaemia. The panel acknowledged small reductions in plasma carotenoid concentrations and recommended adequate fruit and vegetable intake to compensate.

Recent systematic review and meta-analysis of randomized controlled trials found that dietary phytosterol intake significantly decreased total cholesterol (mean difference -13.41 mg/dL), LDL-cholesterol (mean difference -12.57 mg/dL), triglycerides, C-reactive protein, systolic blood pressure, and diastolic blood pressure, while also increasing HDL-cholesterol. Phytosterols did not significantly alter blood glucose or HbA1c. Greater LDL-cholesterol reductions were observed with higher daily phytosterol dosages. The authors noted that most included studies were short-term intervention trials and called for higher quality, longer-duration studies to establish more robust conclusions.

This 2023 systematic review and meta-analysis pooled 125 studies of phytosterol-fortified foods and confirmed a strong LDL-lowering effect, averaging about 0.55 mmol/L. The analysis also showed that dose remained a clear effect modifier and that bread, biscuits, and cereal formats underperformed compared with spreads or similar delivery vehicles. Importantly for the supplement record, the LDL-lowering effect was maintained across subgroup analyses, including concomitant statin treatment. This study modernizes the plant-sterol evidence base by showing that the classic LDL effect remains robust in a large updated pooled dataset.

This systematic review and meta-analysis focused specifically on patients already taking statins, which makes it highly relevant to the real-world add-on use case for plant sterols. Across 15 randomized trials involving 500 participants, plant sterol or stanol enriched diets further lowered total cholesterol and LDL cholesterol by about 0.30 mmol/L beyond statin therapy alone, without meaningful effects on HDL cholesterol or triglycerides. The paper strengthens the additive-with-statins claim because it quantifies the extra LDL reduction directly rather than relying on a broad consensus statement.

This randomized-trial meta-analysis clarifies the main nutritional caveat with chronic plant-sterol use. Across 41 trials and 3306 participants, plant sterol or stanol intake lowered several carotenoid measures, especially beta-carotene and lycopene, while retinol and vitamin D were not meaningfully affected. The changes were modest and were smaller after cholesterol standardization, which supports the common practical advice to keep fruit and vegetable intake solid rather than treating the effect as a major safety problem. For the supplement record, this is the best direct source for the carotenoid-absorption warning.

This double-blind crossover RCT enrolled 50 children (aged 6 to 18) with hypercholesterolemia and tested a phytosterol-enriched spreadable cream for 8 weeks with a 4-week washout. Among the 23 completers, total cholesterol and LDL cholesterol decreased during the phytosterol phase. The study also used lipidomics to characterize changes in phospholipid and sphingolipid profiles underlying the cholesterol reduction. While limited by attrition, this is one of few randomized trials evaluating plant sterols specifically in a pediatric population with familial or primary hypercholesterolemia, extending the evidence base beyond adults.